Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Extra nodal involvement is common in PTLD, but isolated involvement of the central nervous system (CNS) is extremely rare. Given the rarity of primary CNS-PTLD there is no consensus on optimal treatment. We report a patient who developed Epstein-Barr virus related primary CNS-PTLD following allogeneic HSCT who was treated with the monoclonal anti-CD20 antibody rituximab and reduction of immunosuppression. In addition, we review the literature and discuss treatment options for patients with primary CNS-PTLD following allogeneic HSCT.
MeSH terms
-
Adult
-
B-Lymphocytes / metabolism
-
B-Lymphocytes / pathology
-
Brain / pathology
-
Central Nervous System Diseases / complications
-
Central Nervous System Diseases / diagnosis
-
Central Nervous System Diseases / etiology*
-
Female
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Ki-67 Antigen / metabolism
-
Lymphoproliferative Disorders / complications
-
Lymphoproliferative Disorders / diagnosis
-
Lymphoproliferative Disorders / etiology*
-
Magnetic Resonance Imaging
-
PAX5 Transcription Factor / metabolism
-
RNA-Binding Proteins / metabolism
-
Ribosomal Proteins / metabolism
-
Transplantation, Homologous / adverse effects
Substances
-
Ki-67 Antigen
-
PAX5 Transcription Factor
-
PAX5 protein, human
-
RNA-Binding Proteins
-
Ribosomal Proteins
-
RPL22 protein, human